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List of Tables 
 
Table 1 – 2010 Task Force Criteria for the diagnosis of Arrhythmogenic Right Ventricular 
Cardiomyopathy 
 






• Regional RV akinesia, dyskinesia, or aneurysm 
and 1 of the following (end diastole): 
• PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 
mm/m2) 
• PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 
mm/m2) 
• fractional area change ≤33 percent 
 
  
Magnetic resonance imaging: 
 
• Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction 
and 1 of the following: 
• Ratio of RV EDV to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 
(female) 












• Regional RV akinesia or dyskinesia 
and 1 of the following (end diastole): 
• PLAX RVOT ≥29 to <32 mm (corrected for body size [PLAX/BSA] 
≥16 to <19 mm/m2) 
• PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/BSA] 
≥18 to <21 mm/m2) 
• fractional area change >33 percent to ≤40 percent 
 
  
Magnetic resonance imaging: 
 
• Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction 
and 1 of the following: 
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• Ratio of RV EDV to BSA ≥100 to <110 mL/m2 (male) or ≥90 to 
<100 mL/m2 (female) 
• RVEF >40 percent to ≤45 percent\ 
 




• Residual myocytes <60 percent by morphometric analysis (or <50 percent 
if estimated), with fibrous replacement of the RV free wall myocardium in 






• Residual myocytes 60 percent to 75 percent by morphometric analysis (or 
50 percent to 65 percent if estimated), with fibrous replacement of the RV 
free wall myocardium in ≥1 sample, with or without fatty replacement of 
tissue on endomyocardial biopsy 
 




• Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in 
individuals >14 years of age (in the absence of complete right bundle-





• Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the 
absence of complete right bundle-branch block) or in V4, V5, or V6 
• Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of 
age in the presence of complete right bundle-branch block 
 




• Epsilon wave (reproducible low-amplitude signals between end of QRS 





• Late potentials by SAECG in ≥1 of the following 3 parameters in the 
absence of a QRS duration of ≥110 ms on the standard ECG 
 
• Filtered QRS duration ≥114 ms 
• Duration of terminal QRS <40 µV (low-amplitude signal duration) ≥38 
ms 
• Root-mean-square voltage of terminal 40 ms ≤20 µV 
 
• Terminal activation duration of QRS ≥55 ms measured from the nadir of 
the S wave to the end of the QRS, including R', in V1, V2, or V3, in the 






• Nonsustained or sustained ventricular tachycardia of left bundle-branch 
morphology with superior axis (negative or indeterminate QRS in leads II, 







• Nonsustained or sustained ventricular tachycardia of RV outflow 
configuration, left bundle-branch block morphology with inferior axis 
(positive QRS in leads II, III, and aVF and negative in lead aVL) or of 
unknown axis 
• >500 ventricular extrasystoles per 24 hours (Holter) 
 




• ARVC confirmed in a first-degree relative who meets current Task Force 
criteria 
• ARVC confirmed pathologically at autopsy or surgery in a first-degree 
relative 
• Identification of a pathogenic mutation categorized as associated or 





• History of ARVC in a first-degree relative in whom it is not possible or 
practical to determine whether the family member meets current Task 
Force criteria 
• Premature sudden death (<35 years of age) due to suspected ARVC in a 
first-degree relative 




Table 2 – Demographic and anthropometric measures of cohort  
 
 Sex Age (years) Height (cm) Weight (kg) BMI (kg/m2) 
1 Male 46 168 98 35 
2 Male 49 185 81 24 
3 Female 32 163 56 21 
4 Male 15 175 71 23 
5 Male 43 180 89 27 
6 Male 62 170 75 26 
7 Male 30 169 67 23 
8 Female 31 155 49 20 
9 Female 35 163 71 27 
10 Female 20 170 51 18 








Table 3 – CMR and RVA RVEDV 
 
Subject CMR RVEDV (mls) RVA RVEDV (mls) 
1 246.7 130 
2 153 170 
3 244.9 208 
4 230.5 110 
5 196.1 184 
6 210.1 171 
7 158 151 
8 554.7 210 
9 198 116 
10 141.1 121 
11 159.9 141 
 
Table 4 - CMR and RVA RVESV  
 
Subject CMR RVESV (mls) RVA RVESV (mls) 
1 97.4 37 
2 95.7 66 
3 207.3 76 
4 104.6 30 
5 108.4 58 
6 107.3 64 
7 51.6 58 
8 514.1 91 
9 88.5 32 
10 52 48 
11 67.9 58 
 
Table 5 – CMR and RVA RVEF 
 
Subject CMR RVEF (%) RVA RVEF (%) 
1 60.5 71 
2 37.5 61 
3 15.3 64 
4 54.6 73 
5 44.7 68 
6 48.9 63 
7 67.3 61 
8 7.3 57 
9 55.3 72 
10 63.1 60 
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Figure 1 – Spearman’s coefficient of CMR RVEDV and RVA RVEDV 
 
 
































ACM  Arrhythmogenic cardiomyopathy 
ARVC  Arrhythmogenic right ventricular cardiomyopathy 
BSA  Body surface area    
CDH2  Cadherin-2  
CMR  Cardiovascular magnetic resonance 
CPVT  Catecholaminergic polymorphic ventricular tachycardia 
CTNNαT 𝛼-T-catenin 
DES  Desmin 
ECG  Electrocardiogram/electrocardiography 
EDV  End-diastole volume 
EMB  Endomyocardial biopsy/biopsies 
ESV  End-systolic volume 
IMHOTEP African Cardiomyopathy and Myocarditis Registry Programme 
LAO  Left anterior oblique  
LGE  Late gadolinium enhancement  
LMNA  Lamin A/C 
LV  Left ventricle/ventricular 
PLAX  Parasternal long-axis view 
PLN  Phospholamban 
PSAX  Parasternal short-axis view 
RAO  Right anterior oblique 
RV  Right ventricle/ventricular  
RVA  Right ventricular angiogram/angiography 
RVEF  Right ventricular ejection fraction 
RVOT  Right ventricular outflow tract 
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RyR2  Ryanodine-2 receptor 
SAECG Signal averaged electrocardiogram 
SCD  Sudden cardiac death 
SV  Stroke volume 
TFC  Task Force Criteria 
TGF-β3 Transforming growth factor beta 3 
TMEM43 Transmembrane protein 43 
TTN  Titin 








Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy 
characterised by structural and functional changes classically to the right ventricle (RV) – but 
may also involve the left ventricle (LV) – and predisposes to malignant ventricular arrhythmias, 
heart failure and sudden cardiac death (SCD).1 In ARVC, normal myocardium is replaced by 
fibro-fatty tissue. Although RV involvement is the hallmark of ARVC, there can be predominant 
LV involvement or biventricular involvement, with some studies demonstrating up to 52% of 
probands having involvement of the LV.2, 3 Therefore, ARVC may be more appropriately 
considered as simply an arrhythmogenic cardiomyopathy (ACM).  
 
The cardiocutaneous syndromes, Naxos and Carvajal syndromes, are described cutaneous 
disorders associated with ventricular structural abnormalities and ventricular tachycardia (VT). 
In 2000, the discovery that Naxos and Carvajal syndrome were caused by genetic mutations 
in the desmosomal genes, plakoglobin and desmoplakin, respectively, led to the association 
between ARVC and desmosomal gene mutations.1,4 Understanding of the genetic basis of 
ARVC represented a turning point in our understanding of the pathophysiology of ARVC. 
 
ARVC is an autosomal dominant disease with incomplete penetrance and variable expression 
with cardiac desmosomal genes largely thought to be the culprit genes.1,4  ARVC-causing 
mutations are found in genes encoding plakophilin-2, desmoglein-2, desmocollin-2, 
desmoplakin and plakoglobin.4 Desmosomes are critical for the structural integrity of the heart. 
The cadherins (desmoglein and desmocollin) link individual cells, while armadillo proteins 
(plakoglobin and plakophilin) in turn link the cadherin tails to desmoplakin, which anchors the 
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entire desmosomal structure to the intermediate filaments of the cell.5 More recently, our 
department has discovered that mutations in cadherin-2 (CDH-2) can cause ARVC.6,7  
 
The current hypothesis for the pathogenesis of ARVC is that genetic mutations in these 
desmosomal genes lead to abnormal cell-to-cell adhesions, which in turn, cause cell 
uncoupling, inflammation, myocardial cell death and, finally, fibrosis. This hypothesis is 
supported by experimental mouse models with plakophilin, plakoglobin and desmoplakin 
knock-out genes. Mice deficient in these desmosomal genes had myocyte death with resultant 
fibrosis that subsequently provided a substrate for arrhythmias.8 The desmosome hypothesis 
is especially attractive as it explains why strenuous activity would increase cell uncoupling and 
thus accelerate disease progression. It also explains why the disease has a predilection for 
the RV, which is thinner than the LV and thus more susceptible to pathology. 4  
 
The most common mutation worldwide is reported in the plakophilin-2 gene, which is found in 
up to 40% of ARVC probands.9 The South African ARVC registry, coordinated from our centre, 
found similar results in South Africa, with the plakophilin-2 gene mutation being found in 25% 
of cases.10,11  
 
Nondesmosomal genes have also been associated with ARVC, though many of these 
associations have not stood up to epidemiological scrutiny. Nondesmosomal genes include 
transmembrane protein 43 (TMEM43), transforming growth factor beta 3 (TGF-β3), cardiac 
ryanodine-2 receptor (RyR2), desmin (DES), titin (TTN), lamin A/C (LMNA), phospholamban 
(PLN) and 𝛼-T-catenin (CTNNαT).4 In fact, the mutations in the calcium-dependent RyR2 gene 
have been shown to be a cause of catecholaminergic polymorphic ventricular tachycardia 
(CPVT).12 Why nondesmosomal genes should contribute to ARVC is poorly understood. PLN 
seems to be the most common nondesmosomal gene, with a Dutch study finding that this 




In addition to the mechanics of cell-to-cell uncoupling, desmosomal mutations have also been 
implicated in interfering with the canonical/Wnt/β-catenin/Tcf/Lef pathway which regulates 
apoptosis, adipogensis and fibrogenesis.9,14,15 Experiments involving desmoplakin knock-out 
mice have shown that plakoglobin translocates into the nucleus to interfere with this 
pathway.15-17 Since arrhythmias can occur in the concealed phase of ARVC where there is 
insignificant myocardial fibrosis and structural abnormalities, it has been postulated that 
desmosomes, gap junctions and voltage-gated sodium channels are intricately linked and 
dysfunction in one domain impacts on the function of the all the other units.17 This hypothesis 
is supported by the observation that mice with decreased expression of plakophilin-2 exhibit 
a decrease in intercalated disk connexion 43, which plays an important role in sodium channel 
physiology.16 Despite these insights into the genetic basis and disease mechanisms of ARVC, 
what is clear is that our understanding of the pathogenesis of ARVC is far from complete. Only 
58% of patients with ARVC have identifiable genetic mutations, while 16% of healthy control 
individuals also have the same gene abnormalities.1  
 
Currently, ARVC is diagnosed using the 2010 Task Force Criteria (TFC). The 2010 TFC has 
major and minor criteria in 6 categories (Table 1). These categories are: (1) global or regional 
dysfunction and structural alterations, (2) tissue characterisation of the myocardium, (3) 
repolarisation abnormalities, (4) depolarisation/conduction abnormalities, (5) arrhythmias and 
(6) a family history of the disease. A definite diagnosis of ARVC is made with the fulfilment of 
2 major or 1 major and 2 minor criteria. Borderline ARVC is diagnosed with 1 major + 1 minor 
or 3 minor criteria. Possible ARVC is present if 1 major or 2 minor criteria are met.18 
 
The diagnostic criteria have evolved as technology and our understanding of the disease has 
improved. One of the categories in the 2010 TFC is the demonstration of global or regional 
dysfunction and structural alterations. The modalities that can be used to demonstrate this are 
two-dimensional echocardiography, cardiovascular magnetic resonance (CMR) and right 
ventricular angiography (RVA). Two-dimensional echocardiography has the benefit of being 
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noninvasive, but as the RV lies behind the sternum and has a curved shape, image acquisition 
is often problematic and suboptimal. RVA provides better image acquisition than two-
dimensional echocardiography but is invasive, involves ionising radiation and has the potential 
for complications. Although endomyocardial biopsies (EMB) can be performed at the time of 
RVA, its use is limited by the fact that sampling the thin dyskinetic RV free wall, which is the 
most likely area to provide a specimen with the highest yield, carries a much higher risk of 
complications than if another area was sampled. Major criteria for RVA findings are regional 
RV akinesia, dyskinesia or aneurysms.18  
 
CMR has emerged as the imaging modality of choice as it can achieve better imaging of the 
RV compared to two-dimensional echocardiography and is noninvasive compared to RVA. 
CMR can detect fat infiltration, wall motion abnormalities, myocardial fibrosis as well as 
measure ventricular size accurately.19 Major criteria for CMR are regional RV akinesia, 
dyskinesia or dyssynchronous contraction plus one sign of functional impairment. Functional 
impairment is defined as the ratio of RV end-diastolic volume (RVEDV) to body surface ratio 
being >110 mL/m2 for males and >100 mL/m2 for females or RV ejection fraction (RVEF) of 
<40%. It should however be noted that the 2010 TFC do not make provision for CMR detection 






Rationale for Study 
 
CMR and RVA both investigate functional and structural abnormalities of the RV. The RVA is 
the older of the two modalities. To date, there have been limited data comparing CMR and 
RVA, and no such studies from the African continent. This study compares CMR and RVA in 
the assessment of ARVC in the South African ARVC registry.  
 
Aims and objectives  
 
The aim of this study was to compare CMR and RVA in the assessment of ARVC in the South 








1.  Comparison of CMR and RVA end-systolic volumes (ESV) and EDV 
2. Comparison of CMR and RV angiography RVEF 




We hypothesise that CMR and RV angiography will be comparable in the detection of 
structural abnormalities, ventricular volumes and ejection fractions. We also hypothesise that 
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Pubmed was searched using combinations of the following terms: “arrhythmogenic right 
ventricular cardiomyopathy’’, “Southern Africa”, “South Africa”, “cardiovascular magnetic 
resonance”, “magnetic resonance imaging”, “angiography” and “angiogram”.  
 
Summary of literature 
 
ARVC is a rare, inherited cardiomyopathy characterised by fibro-fatty infiltration of mostly the 
RV that predisposes to ventricular arrhythmias and SCD. 1 It is an autosomal dominant disease 
with incomplete penetrance and variable expression.1, 2 The cardiac desmosomal genes, 
plakophilin-2, desmoglein-2, desmocollin-2, desmoplakin and plakoglobin are the main 
causative genes in ARVC.2 The current hypothesis for the pathogenesis of ARVC is genetic 
mutations in desmosomal genes leading to abnormal cell-to-cell adhesions, which in turn, 
cause cell uncoupling, inflammation, myocardial cell death and, finally, fibrosis. The most 
common mutation worldwide is the plakophilin-2 gene, which is found in up to 40% of cases.3  
 
Nondesmosomal genes have also been associated with ARVC, though many of these 
associations have not stood up to epidemiological scrutiny. Nondesmosomal genes implicated 
in ARVC development include TMEM43, TGF-β3, RyR2, DES, TTN, LMNA, PLN and 
CTNNαT.4 Mutations in the calcium-dependent RyR2 gene have been shown to be a cause 
of CPVT.  What is clear is that our understanding of the pathogenesis of ARVC is far from 
complete. Whilst only 58% of patients with ARVC have identifiable genetic mutations, 16% of 




ARVC is a complex disease with no single gold standard test. The diagnosis is established 
using the 2010 TFC. The 2010 TFC has major and minor criteria in 6 categories (Table 1).5 
These categories are:  
 
(1) global or regional dysfunction and structural alterations 
(2) tissue characterisation of the myocardium 
(3) repolarisation abnormalities 
(4) depolarisation/conduction abnormalities 
(5) arrhythmias   
(6) family history of the disease.  
 
A definite diagnosis of ARVC is made with the fulfilment of 2 major or 1 major and 2 minor 
criteria. Borderline ARVC is diagnosed with 1 major and 1 minor or 3 minor criteria. Possible 
ARVC is present if 1 major or 2 minor criteria are met.5  
 
ARVC in South Africa 
 
The first case of ARVC in Africa was diagnosed in 2000, with the South African ARVC registry 
also established in 2000.6,7 A study of the profile of South African ARVC patients showed that 
80% of affected individuals were white, while the most common gene mutation was the 
plakophilin-2 gene, found in 25% of probands.7 Mortality for the South African cohort was 
2.8%, with the mean age of death being 20 years younger than a French series.7 Our group 
concluded that ARVC in Southern Africa, with the exception of age of death, was similar to 
that reported in the international literature. In the South African ARVC registry, the 
predominance of white probands was postulated to be due to racial healthcare inequalities 
and differential healthcare access, although a founder effect could not be excluded.7  More 
recently, our group postulated new gene mutation in CDH-2 was responsible for ARVC.8  The 
newly reported ARVC-causing mutation was found in 2.7% probands in the South African 
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ARVC registry.8 ARVC caused by CDH-2 mutations has also been recently confirmed by a 
group from the Mayo Clinic.9 From the literature, and based on our experience, it is thus 
reasonable to infer that ARVC in South Africa is similar to international trends, although the 
patients and age of death is younger. These observations suggest that a more aggressive 
approach to treatment in our setting is warranted.   
 
Utility of RV angiography in ARVC 
 
RVA allows for assessment of the structure and function of the RV, making it useful in the 
diagnosis of ARVC. The sensitivity and specificity of angiography is considered high. A small 
study of 17 probands by White, et al found a 100% specificity and sensitivity for RVA.10  A 
positive predictive value of 85% and a negative predictive value of 95% has been reported in 
the literature for RVA.10,11 It should, however, be noted that acquiring angiography images can 
be technically difficult with incorrect catheter position, for example, giving sub-optimal images 
by inducing ectopic beats. Failing to distribute the contrast throughout the RV correctly can 
also impact on volume calculations. Ahmed, et al also noted poor inter-observer variations in 
qualitative measurements which is of concern as the 2010 TFC major criteria for angiography 
are limited to qualitative measurements rather than quantitative measurements.12 
 
Angiography has the advantage of allowing histology to be attained via EMB at the time of the 
procedure. The sensitivity of histology, however, is considered poor as the low yield septal 
area, rather than the RV free wall, is most often sampled due to fear of complications.13,14 
From the literature, RVA is considered as an excellent test in the diagnosis of ARVC, provided 







Utility of CMR in ARVC 
 
CMR is an attractive imaging modality, as it is safe, reproducible and can achieve excellent 
images of the RV in any orthogonal plane. Importantly, CMR is the gold-standard technique 
for assessment of RV volumes. CMR has excellent spatial and temporal resolution and does 
not involve any ionising radiation, compared to RVA. 15 CMR can assess anatomical 
abnormalities such as wall motion abnormalities, ventricular size, RVEF and detect fatty 
infiltration and myocardial fibrosis.15 The importance of CMR was underscored by a study 
conducted in a paediatric population which concluded that CMR was needed in half of the 
study patients in order to secure the diagnosis of definite ARVC.16 In this study, the authors 
concluded that, in decreasing order of importance, the contribution of individual investigations 
to the diagnosis of ARVC was an abnormal CMR, positive family history, EMB findings, 
abnormal depolarisation on electrocardiography (ECG), abnormal echocardiogram, abnormal 
repolarisation on ECG, and finally, the presence of arrhythmias.16 Similarly, in the South 
African ARVC registry, CMR was useful for the confirmation of the diagnosis of ARVC in the 
majority of probands.17  
 
The original 1994 TFC required the demonstration of RV dilation, aneurysms and a reduction 
in RVEF.18 These criteria were criticised as being too subjective and were subsequently 
revised. The revised 2010 Task Force CMR criteria required the demonstration of both 
structural RV abnormalities and functional abnormalities in the form of quantitative cut-offs in 
RVEF and RVEDV.5 These cut-off values in RVEF and EDV were derived after comparing 462 
normal patients in the Multi-Ethnic Study of Atherosclerosis study to 44 North American 
Multidisciplinary ARVC study probands and was targeted to achieve a specificity of 95% once 
a major criteria was fulfilled.19 There have been many studies to assess the impact of the new 
criteria on the diagnosis of ARVC. Most of these studies have noted a reduction in patients 
meeting major and minor criteria after the introduction of the 2010 TFC, which is not surprising 




Major CMR criteria have been reported in the literature to have a sensitivity of between 68% 
and 100%, with specificity of up to 94%.21-23  Femia, et al showed that the positive predictive 
value of CMR is 55%, while negative predictive value is 100%.20 CMR has been shown to 
have excellent inter-observer correlation, with correlation coefficients between observers for 
RVEDV, RVESV and RVEF being in excess of 90%.23  
 
The detection of intra-myocardial fat is a very attractive diagnostic parameter in the diagnosis 
of ARVC. However, studies have shown that the sensitivity and specificity of intra-myocardial 
fat is quite variable, ranging from 22% to 100%.23-25 This has been attributed to the RV being 
so thin walled that, practically, it is difficult to separate normal epicardial from pathological 
myocardial fat.24,25 Fat infiltration is also not specific for ARVC as it can also be present in the 
elderly, obese, steroid users and in right ventricular outflow tract tachycardias.24,25  
 
Late gadolinium enhancement (LGE), which detects myocardial fibrosis, is another technique 
which may improve CMR diagnostics, although Marra, et al found that invasive endocardial 
voltage mapping was significantly more sensitive than contrast-enhanced CMR in the 
identification of RV scars.26 It follows that CMR, as a diagnostic and prognostic tool, should be 
used synergistically rather than alone in the diagnosis of ARVC. Indeed, Aquaro, et al showed 
that pre- and postcontrast signal abnormalities markedly increased the sensitivity of CMR, and 
that by combining the traditional functional parameters with signal abnormalities yielded a 96% 
sensitivity and 100% specificity.27 In addition to the diagnosis of ARVC, CMR can be useful in 
prognosticating probands with ARVC, with an abnormal CMR having a 96.9% positive 
predictive value for adverse cardiac events, and with involvement of the LV being an especially 
strong predictor.28 
 
In summary, CMR is an important imaging tool in the diagnosis of ARVC. The variable 
sensitivity in the literature may be attributable to the evolving accuracy of CMR analytic tools 
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relative to when the studies were done. Although sensitivity is variable, specificity is 
consistently high in the literature. Other than the traditional structural and functional 
parameters, new techniques have been developed that may enhance CMR capabilities, 
including presence of LGE. It is highly likely that an updated TFC will incorporate these 
emerging CMR techniques in the future.   
 
Comparison of CMR and RVA 
 
There have been few studies in which compared RVA to CMR directly.  
 
In 2004, White, et al examined 17 patients who had presented with arrhythmias and were 
being evaluated for ARVC. Out of this cohort, 7 were subsequently diagnosed with definite 
ARVC, according to 1994 TFC. CMR sensitivity and specificity for this cohort was 86% and 
60%, respectively, while angiography had a sensitivity and specificity of 100%.10 In 2012, Indik, 
et al studied 17 probands from the North American ARVC registry who had undergone both 
CMR and RVA. This study noted a correlation coefficient of 72% for RVEDV, 68% for RVEF, 
with RVA volumes being generally greater than CMR volumes.29 
 
RVA is an established and tested technique. CMR on the other hand is newer and has 
advantages of being noninvasive, providing better viewing planes of the RV and allows for fat 
and fibrosis detection.  Since the publication of the comparative study in 2004,10 CMR 
protocols have become more refined, machines more sophisticated and interpreters much 
more experienced. It is likely that CMR will provide greater reproducibility than RVA, as has 
been recently reported.29 Indeed, the revised 2010 TFC no longer includes quantitative criteria 






Existing gaps in the literature 
 
The only 2 studies that have been performed, comparing CMR and RVA, are dated and have 
involved small numbers. Further, there have also been no studies to document the African 
experience. The University of Cape Town and Groote Schuur Hospital host the South African 
ARVC registry and the African Cardiomyopathy and Myocarditis Registry Program 
(IMHOTEP) and are in an opportune position to have the capacity to undertake such a 
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The study was a retrospective analysis of ARVC cases from the South African ARVC and 
IMHOTEP registries. RVESV, RVEDV, RVEF for both CMR and RVA were measured. The 
presence of structural abnormalities was also noted. All RVA and CMR data were interpreted 




The study population consisted of definite, possible and borderline ARVC cases from these 
afore-mentioned registries, who had both CMR and RVA data.    
 
Data collection and management 
 
The collected data was entered onto an electronic database that was password protected to 
ensure privacy. Each proband had the following data entered: CMR RVEDV; CMR RVESV; 
RVA RVEDV; RVA RVESV; presence of aneurysms/regional wall abnormalities on CMR; 
presence of aneurysms/regional wall abnormalities on RVA. No personal identifiable data 




CMR: CMR studies were performed using a 1.5 T MR system (Avanto and Aera, Siemens 
Healthcare, Germany). A 32-channel phased-array chest coil was used for all data acquisition, 
except for short-Tau inversion recovery (STIR) imaging, for which the body coil was used. A 
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complete stack of short axis images was obtained during breath hold and cardiac gating for 
cine and LGE imaging. LGE imaging was performed using a T1-weighted phase-sensitive 
inversion recovery sequence about 8 minutes after intravenous administration of contrast 
agent (0.15 mmol/kg body weight).  
 
Analysis of LV and RV ejection fraction was performed using Argus software (Version VB17, 
2011, Siemens Medical Solutions). LV and RV short axis epicardial and endocardial borders 
were manually contoured at end-diastole and end-systole. LV end-systolic (LVESV) and end-
diastolic (LVEDV) volumes were used to calculate stroke volume (SV) and ejection fraction 
(EF) – (EF = SV/EDV). Myocardial mass was also calculated by subtracting the endocardial 
volume from the epicardial volume, based on prior knowledge of myocardial specific gravity 
(1.05 g/cm3). Left atrial diameter was measured in the LV outflow tract (3-chamber) view. The 
RVEDV and RVESV were calculated in a similar fashion, as above.  
 
Images were evaluated qualitatively for the presence or absence, pattern (subendocardial, 
midwall, subepicardial, transmural) and regional distribution of LGE areas by three observers, 
each with at least 4 years of CMR experience. The detection of LGE was made by consensus 
of all 3 observers. In addition, endocardial and epicardial regions of interest (ROI) were 
manually contoured in the LGE images, together with a reference ROI in the anterior LV wall 
without visual LGE, and focal areas of LGE were defined quantitatively as those with SI ≥ 2.0 
standard deviations above the mean SI of normal myocardium. 
 
RVA: For calculation of RV angiographic volumes, the 30° right anterior oblique (RAO) and 
60° left anterior oblique (LAO) views were utilised. The RV angiographic volumes were 
analysed blindly by two observers, independently. A cardiac cycle was analysed that had 
good contrast opacification of the RV and not immediately proceeded by a premature 
ventricular contraction. The diastolic and systolic images were selected, and a contour 
drawn in each phase. The area within the contour was then calculated. The length-scale 
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was calibrated by measuring the projected size of the magnified angio-catheter shaft within 
the RV, which was usually a pigtail 5Fr catheter, to allow an accurate and reproducibly 
consistent measurement. The RV volume was then assessed by using both the RAO and 
LAO projections (VTWO-VIEW) or by using the RAO projection alone (VRAO).  
 
VTWO-VIEW was calculated as: 
VTWO-VIEW = 0.6 ∗ ARAO ∗ ALAO / LRAO + 3.9(ml)      (1) 
where ARAO was the projected area within the drawn contour in the RAO view, ALAO was the 
projected area in the LAO view, and LRAO was the projected distance in the RAO view from 
the pulmonic valve to the point that bisected the inferior wall. 
 
The ejection fraction was then computed as follows: 
RVEFTWO-VIEW = (VTWO-VIEW-DIA − VTWO-VIEW-SYS) / VTWO-VIEW-DIA       (2) 
where VTWO-VIEW-DIA was the volume computed at end-diastole and V TWO-VIEW-SYS was the 
volume computed at end-systole of the chosen cardiac cycle by Equation 1.  
 
Using the RAO view alone, the volume was calculated as: 
VRAO = (0.4 ∗ ARAO ∗ ARAO / LRAO + 3.9) ∗ 0.88 + 7.71 ml      (3) 
 
The RVEF was computed using the RAO computed volumes at end-diastole and end-systole 
as follows: 
RVEFRAO = (VRAO-DIA − VRAO-SYS) / VRAO-DIA       (4) 
where VRAO-DIA was the volume computed at end-diastole and VRAO-SYS was the volume 
computed at end-systole of the chosen cardiac cycle, by the RAO volume formula (Equation 






Ethical considerations and obtaining informed consent 
 
This proposal was submitted to the University of Cape Town Human Research Ethics 
Committee. This study was a substudy of a study which has already been given ethics 
approval for the ARVC Registry of South Africa (HREC Reference number: 047/2003) and 
IMHOTEP study (HREC Reference number: 766/2014). Informed consent has therefore 
already been obtained from participants and was not obtained again as this was a 




Descriptive statistics were used to summarise patient characteristics. Continuous variables 
were summarised as mean ± standard deviation, and minimum and maximum range where 
applicable. Categorical variables were presented as frequencies and percentages.  
Spearman’s rank correlation was used to analyse the strength and direction of the linear 
relationship between RVA and CMR measures.  Bland-Altman plots were used to assess the 
agreement between angiogram and MRI measurements. Limits of agreement (95% lower and 
upper bounds) were calculated as the mean difference ± 2 standard deviations.  All analysis 
was performed using Stata v.14.1 software (StataCorp, College Station, TX, USA).  
 
Risks and benefits 
 
Risks: This study was a retrospective cross-sectional study of data already collected. There 
was therefore no risk to participants.  
 
Benefits: CMR is far less invasive with less complications than RVA. If the findings of the 
study confirm that CMR is similar or superior to RVA in the assessment of the RV in ARVC, 
this could improve patient safety as CMR is not an invasive technique. There was no obvious 
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benefit for the participants of this study, but such work may benefit future patients suspected 
of ARVC.  
 
Publication and dissemination 
 
The results of the study will be made available through the University of Cape Town Masters 
of Medicine catalogue. The study findings shall also be made available through published 










Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited 
cardiomyopathy characterised by structural changes to mostly the right ventricle (RV) that 
predisposes to ventricular arrhythmias heart failure and sudden cardiac death. ARVC is 
diagnosed using the 2010 Task Force Criteria which include RV angiography (RVA) and 
cardiovascular magnetic resonance (CMR). There has been a dearth of studies to document 
the comparison of the performance of CMR and RVA, and none undertaken in Africa. The aim 
of this study was to compare CMR and RVA in the assessment of ARVC in the South African 
ARVC registry. 
 
Methods: The study is a retrospective analysis of definite, possible and borderline ARVC 
cases from the South African ARVC registry and the African Cardiomyopathy and Myocarditis 
Registry Program (IMHOTEP) that have both CMR and RVA data. RV end-systolic and 
diastolic volumes, RV ejection fractions and the presence of absence of structural 
abnormalities derived from RVA and CMR are compared. Sensitivity of CMR and RVA for the 
diagnosis of definite, possible and borderline ARVC was also calculated.  
 
Results: A total of 11 patients out of 62 from the registry met the inclusion criteria. The 
Spearman’s coefficient for RV end-systolic volume was 0.48 (p=0.12). The Spearman’s 
coefficient for RV end-diastolic volume was 0.28 (p=0.4). The Spearman’s coefficient for RV 
ejection fraction was 0.06 (p=0.85). CMR detected regional wall abnormalities in 4 out of 11 
patients while RVA did not detect any regional wall abnormalities. Sensitivity of CMR and RVA 




Conclusions: We show that South African ARVC patients had poor correlation between CMR 
and RVA parameters, and CMR was also more likely to reveal RV free wall regional wall 
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy 
characterised by structural changes to mostly the right ventricle (RV) that predispose to 
ventricular arrhythmias, heart failure and sudden cardiac death (SCD).1 ARVC is diagnosed 
using the 2010 Task Force Criteria (TFC) (Table 1).2 The 2010 TFC have major and minor 
criteria in 6 categories (Table 1). These categories are: (1) global or regional dysfunction and 
structural alterations, (2) tissue characterisation of the myocardium, (3) repolarisation 
abnormalities, (4) depolarisation/conduction abnormalities, (5) arrhythmias and (6) a family 
history of the disease. A definite diagnosis of ARVC is made with the fulfilment of 2 major or 
1 major and 2 minor criteria. Borderline ARVC is diagnosed with 1 major + 1 minor or 3 minor 
criteria. Possible ARVC is present if 1 major or 2 minor criteria are met.2 The diagnostic criteria 
have evolved as technology and our understanding of the disease has improved. One of the 
categories in the 2010 TFC is the demonstration of global or regional dysfunction and 
structural alterations. The modalities that can be used to demonstrate this are two dimensional 





RVA is invasive and has the potential for complications. Although endomyocardial biopsies 
(EMB) can be performed at the time of RVA, its use is limited by the observation that sampling 
the thin dyskinetic RV free wall, which is the most likely area to produce the highest yield, 
carries the highest risk of complications. CMR is the imaging modality of choice as it can 
achieve more accurate quantification of RV volumes and imaging of the RV structure 
compared to 2-dimensional echocardiography, is noninvasive and without ionising radiation 
when compared to RVA.3,4 CMR can detect fat infiltration, wall motion abnormalities, 
ventricular sizes and myocardial fibrosis in the RV.3 Major criteria for CMR are regional RV 
akinesia, dyskinesia or dyssynchronous contraction plus one sign of functional impairment.2 
 
There have been few studies which have compared RVA to CMR directly. In 2004, White, et 
al examined 17 patients who had presented with arrhythmias and were being evaluated for 
ARVC.5 Out of this cohort, 7 were subsequently diagnosed with definite ARVC according to 
1994 TFC. CMR sensitivity and specificity for this cohort was 86% and 60%, respectively, 
while RVA had a sensitivity and specificity of 100%.5 In the other comparative study, published 
in 2012, Indik, et al studied 17 probands from the North American ARVC registry who had 
undergone both CMR and RVA, and noted a correlation coefficient of 0.72 for RV end-diastolic 
volume (RVEDV), 0.68 for RV ejection fraction (RVEF) with RVA volumes generally bigger 
than CMR.6 
 
There have been no studies to document comparisons of CMR and ARVC on the African 
continent. The University of Cape Town hosts the African Cardiomyopathy and Myocarditis 
Registry Program (IMHOTEP) and the South African ARVC registry. Therefore, we aimed to 










The study was a retrospective analysis of definite, possible and borderline ARVC cases from 
the IMHOTEP and South African ARVC registries that had both CMR and RVA data. RV end-
systolic volume (RVESV), RVEDV, RVEF and the presence of structural abnormalities were 
noted in CMR and RVA. Data were entered onto an electronic database that was password 
protected to ensure privacy.  
 
CMR studies were performed using a 1.5 T MR system (Avanto and Aera, Siemens 
Healthcare, Germany). A 32-channel phased-array chest coil was used for all data acquisition. 
A complete stack of short axis images was obtained during breath hold and cardiac gating for 
cine and LGE imaging. LGE imaging was performed using a T1-weighted phase-sensitive 
inversion recovery sequence about 8-15 minutes after intravenous administration of contrast 
agent (0.15 mmol/kg body weight).  
 
Analysis of LV and RV ejection fraction was performed using Argus software (Version VB17, 
2011, Siemens Medical Solutions). LV and RV short axis epicardial and endocardial borders 
were manually contoured at end-diastole and end-systole. LV end-systolic (LVESV) and end-
diastolic (LVEDV) volumes were used to calculate stroke volume (SV) and ejection fraction 
(EF) – (EF = SV/EDV). Myocardial mass was also calculated by subtracting the endocardial 
volume from the epicardial volume, based on prior knowledge of myocardial specific gravity 
(1.05 g/cm3). Left atrial diameter was measured in the LV outflow tract (3-chamber) view. The 
RVEDV and RVESV were calculated in a similar fashion, as above.  
 
For calculation of RV angiographic volumes, the 30° right anterior oblique (RAO) and 60° 
left anterior oblique (LAO) views were utilised. The RV angiographic volumes were analysed 
blindly by two observers, independently. A cardiac cycle was analysed that had good 
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contrast opacification of the RV and not immediately proceeded by a premature ventricular 
contraction. The diastolic and systolic images were selected, and a contour drawn in each 
phase. The area within the contour was then calculated. The length-scale was calibrated by 
measuring the projected size of the magnified angio-catheter shaft within the RV, which was 
usually a pigtail 5Fr catheter, to allow an accurate and reproducibly consistent 
measurement. The RV volume was then assessed by using both the RAO and LAO 
projections (VTWO-VIEW) or by using the RAO projection alone (VRAO).  
 
VTWO-VIEW was calculated as: 
VTWO-VIEW = 0.6 ∗ ARAO ∗ ALAO / LRAO + 3.9(ml)      (1) 
where ARAO was the projected area within the drawn contour in the RAO view, ALAO was the 
projected area in the LAO view, and LRAO was the projected distance in the RAO view from 
the pulmonic valve to the point that bisected the inferior wall. 
 
The ejection fraction was then computed as follows: 
RVEFTWO-VIEW = (VTWO-VIEW-DIA − VTWO-VIEW-SYS) / VTWO-VIEW-DIA       (2) 
where VTWO-VIEW-DIA was the volume computed at end-diastole and V TWO-VIEW-SYS was the 
volume computed at end-systole of the chosen cardiac cycle by Equation 1.  
 
Using the RAO view alone, the volume was calculated as: 
VRAO = (0.4 ∗ ARAO ∗ ARAO / LRAO + 3.9) ∗ 0.88 + 7.71 ml      (3) 
 
The RVEF was computed using the RAO computed volumes at end-diastole and end-systole 
as follows: 
RVEFRAO = (VRAO-DIA − VRAO-SYS) / VRAO-DIA       (4) 
where VRAO-DIA was the volume computed at end-diastole and VRAO-SYS was the volume 
computed at end-systole of the chosen cardiac cycle, by the RAO volume formula (Equation 




The study was approved by the University of Cape Town Human Research Ethics Committee. 
This study was a substudy of the ARVC Registry of South Africa (HREC Reference number: 
047/2003) and IMHOTEP study (HREC Reference number: 766/2014). Informed consent had 
therefore already been obtained from participants and was not obtained again as this was a 
retrospective assessment of data that already had been collected.  
 
Descriptive statistics were used to summarise patient characteristics. Continuous variables 
were summarised as mean ± standard deviation and minimum and maximum range. 
Categorical variables were presented as frequencies and percentages.  Spearman’s rank 
correlation was used to analyse the strength and direction of the linear relationship between 
RVA and CMR measures.  Absolute error was calculated for every subject for each measure. 
Mean difference was calculated as the difference between RVA and CMR measures. Bland-
Altman plots were used to assess the agreement between angiogram and MRI 
measurements. Limits of agreement (95% lower and upper bounds) were calculated as the 
mean difference ± 2 standard deviations.  Plots were observed to assess whether data values 
fall within ± 2s of the mean difference.  All analysis was performed using Stata v.14.1 software 




Demographic and anthropometric measures 
 
11 patients out of 62 from the IMHOTEP and South African ARVC registries met the inclusion 
criteria of the study. Of these 11 ARVC patients, 6 were male; the mean age was 36 ± 14 
years (range of 15 to 62 years) (Table 2). The mean height was 1.69 ± 8.48 m and mean 




Comparative analysis of RVEDV 
 
CMR derived mean RVEDV was 226 ± 155 ml, with a range of between 141 and 554 ml (Table 
3). RVA derived mean RVEDV was 155 ± 35 ml, with a range of between 110 and 210 ml. 
The Spearman’s coefficient for RVEDV was 0.28 (p=0.4) (Figure 1). Bland-Altman analysis 
showed that the bias (mean difference in scores ± standard deviation) between MRI and 
angiogram RVEDV was 71 ± 101 ml (Figure 2). The upper limit of agreement is 273 ml and 
the lower limit of agreement is -131 ml. CMR derived RVEDV were greater than those derived 
from RVA.  
 
Comparative analysis of RVESV 
 
CMR derived mean RVESV was 135 ± 132 ml, with a range of between 51 and 514 ml (Table 
4). RVA derived mean RVESV was 56 ± 18 ml with range of between 30 and 91 ml. The 
Spearman’s coefficient for RVESV was 0.48 (p=0.12) (Figure 3). Bland-Altman analysis 
showed that the bias between CMR and RVA value for RVESV was 79 ± 36 ml (Figure 4). 
The upper limit of agreement was 319 ml and lower limit of agreement of -160 ml. Similar to 
above, we found that RVA underestimated RVESV compared to CMR.  
 
Comparative analysis of RVEF 
 
CMR derived RVEF was 46 ± 19 %, with a range of between 7.3 and 67% (Table 5). RVA 
derived RVEF was 64 ± 5 %, a range of between 57 and 73%. The Spearman’s coefficient for 
RVEF was 0.06 (p=0.85) (Figure 5). Bland-Altman analysis showed that mean difference 
between CMR and RVA value is 18 ± 5.5 % (Figure 6).  The upper limit of agreement is 19% 






Comparative analysis of RV wall motion abnormalities 
 
CMR detected regional wall abnormalities in 4 of 11 (36%) ARVC patients, while RVA did not 





Out of the 62 definite, possible and borderline borderline cases, 27 had CMR data. 13 of these 
27 ARVC patients with CMR fulfilled major criteria for ARVC based on CMR imaging criteria. 
Sensitivity for a major CMR criterion was therefore 48%. There were 38 RVA available for 
analysis from the 62 patients in the registries. Of these 38 patients with RVA, 21 fulfilled major 
criteria for ARVC based on RVA imaging criteria. Sensitivity for RVA major criteria was 
therefore 55%. Specificity could not be calculated as we did not have the overall denominator 




We compared the diagnostic performance of CMR and RVA in 11 patients with ARVC. We 
found that (1) the patients were young, with a mean age of 37 years, (2) CMR derived end-
diastolic and end-systolic volumes were greater, (3) CMR derived RVEF was lower, (4) there 
was great variability between CMR and RVA measures, with poor correlation on Bland-Altman 
analysis, (5) only CMR revealed focal dyskinesia of the RV, and (6) that diagnostic sensitivity 
was poor for both modalities in this study. We believe these data have significant implications 
for clinical practice, and suggest that CMR may be a preferred diagnostic tool for imaging in 
ARVC. First, CMR is noninvasive and does not involve ionising radiation. Second, CMR was 




Our hypothesis in this study was that there would be a high degree of correlation between 
CMR and RVA, which was not supported by the results. In fact, our study revealed poor 
correlation between CMR and RVA with worsening Spearman’s correlation for RVESV, 
RVEDV and RVEF, respectively. Several possibilities exist to explain the discrepant results, 
including the small sample size, variable RVA technique, and temporal differences in the 
acquisition of the data from the 2 imaging modalities.  
 
Of interest, our observations of the low sensitivity of CMR (48%) and RVA (55%) were not in 
keeping with previously published data. RVA has been reported to have a sensitivity of 100%.5 
Similarly, prior studies have reported a CMR sensitivity of 68%-100%.7-9 The diagnostic 
accuracy of CMR was assessed in a series of 232 patients undergoing evaluation for 
suspected ARVC using the 1994 TFC.9 In this series, 64 patients fulfilled 1994 TFC for the 
diagnosis of ARVC, 63 fulfilled diagnostic criteria modified for familial ARVC, and another 7 
were obligate gene carriers. The following were noted: (1) 183 of CMR studies were 
interpreted as diagnostic or strongly suspicious for ARVC; and (2) all patients who fulfilled 
1994 TFC modified for familial ARVC, or those who were obligate gene carriers had abnormal 
CMR results (diagnostic or strongly suspicious), thus giving a sensitivity and specificity of CMR 
for clinical ARVC of 100% and 50%, respectively.9 Possible reasons for the low sensitivity 
observed in our study are indicated in the study limitations described below.  
 
Nowadays, in most centres, RVA is rarely performed in patients suspected of having ARVC, 
reflecting the fact that CMR provides high-quality quantitative information on RV size and 
function, as well as tissue characteristics through use of LGE imaging. However, in centers 
where CMR is not available, or in patients in whom EMB is planned, RVA is still performed. 
CMR enables identification of global and regional ventricular dilation, global and regional 
ventricular dysfunction, intramyocardial fat, LGE and focal wall thinning.8-13 Importantly, 
neither wall thinning nor intramyocardial fat is included in the diagnostic criteria for ARVC, and 
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they should not be relied on for diagnosis. Further, CMR abnormalities are unlikely in the 
absence of ECG, echocardiographic, and/or arrhythmic manifestations of ARVC, though the 
possible role of LGE as an isolated, early marker of disease expression requires additional 
evaluation.14 
 
While not assessed in this study, CMR may play an important role in the risk stratification of 
ARVC patients. Among a cohort of 175 ARVC patients (52 definite, 50 borderline, and 73 
possible by 2010 revised TFC) who underwent CMR and were followed for a median of 4.3 
years, 35 (20%) patients experienced a hard cardiac event (SCD, resuscitated cardiac arrest, 
or appropriate ICD shock).15 Of the 35 patients with an event, 34 had CMR abnormalities 
(defined as RV or LV wall motion abnormality, RV or LV dilation, RV or LV systolic dysfunction, 
fat infiltration, or LGE), suggesting that patients with a normal CMR are at low risk for cardiac 
arrhythmic events. Measurements of myocardial strain by CMR correlate well with scar (as 
detected by LGE or by electroanatomic mapping during invasive electrophysiology studies) 
and may be helpful in identifying patients at risk for VT with arrhythmogenic substrate for 
ablation.16 Indeed, in our study, CMR was able to detect wall motion abnormalities in 36%, 
when these were not detected on RVA. 
 
Our data suggest that CMR may be a more reliable tool for the assessment of RV volumes 
and function in ARVC. However, concerns with CMR have been noted in the published 
literature. First, although some CMR parameters are highly specific for gene-carrier status 
(e.g., specificity of 100% for each of these three parameters: RV dilation and/or systolic 
impairment, RV LGE, and severe RV segmental dilation/regional wall motion 
abnormalities and/or aneurysms), others demonstrated low specificity (e.g., specificity of 56% 
for abnormal trabeculations and 44% for mild RV localized dilation and/or regional wall motion 
abnormalities).9 Second, CMR interobserver variability in identifying features of ARVC has 
been noted, and substantial interobserver variability may be seen identified between readers, 
likely related to lack of experience with CMR in the diagnosis of ARVC.8,12,17 Consequently, 
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CMR should ideally be performed in a center with expertise in the evaluation of ARVC with 
CMR. 
 
This study has several limitations. First, it has all the flaws of a retrospective design. Second, 
the sample size of 11 ARVC patients included is small. Third, the RVA technique was noted 
to be quite variable and the imaging planes used for RVA were not consistent. Fourth, the 
readers for CMR and RVA were not all blinded to the results. Fifth, the CMR and RVA were 
not always performed at the same time point and may explain some of the discrepancies noted 
between the two, due to disease progression between imaging time points. Sixth, our study 
was unable to assess specificity of CMR and RVA, as we did not have data on total numbers 
of patients who underwent imaging and subsequently found not have the disease. 
Nonetheless, despite these limitations, we think that this study provides useful insights on the 




In conclusion, we compared the diagnostic performance of CMR and RVA in patients with 
ARVC and found that CMR reported greater volumes, lower global systolic function, and was 
more likely to reveal RV dyskinesia or dyssynchrony. There was great variability between CMR 
and RVA measures of cardiac structure and function and poor correlation on Bland-Altman 
analysis. Finally, in our study, the diagnostic sensitivity of both CMR and RVA was low 
compared to existing literature. It would be ideal for these observations to be confirmed in 
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